PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10616997-0	1999	Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass grafting.	Trimetazidine	63-76	troponin T1, slow skeletal type	Homo sapiens	15-25	
25871315-7	2015	The pooled effect sizes showed significantly lower postoperative levels of CK, CK-MB, TnT and TnI in the trimetazidine-treated CABG patients relative to control CABG patients.	Trimetazidine	105-118	troponin T1, slow skeletal type	Homo sapiens	86-89	
25871315-9	2015	In both the <=12 and >12 h post-CABG subgroup analyses, significant differences in CK, CK-MB, TnT and TnI were detected between the trimetazidine-treated CABG patients relative to control CABG patients.	Trimetazidine	138-151	troponin T1, slow skeletal type	Homo sapiens	100-103	
10616997-1	1999	BACKGROUND: The aim of the present study was to evaluate potential myocardial protection by trimetazidine by measurement of the cardiac marker protein troponin T (TnT) during coronary bypass operations.	Trimetazidine	92-105	troponin T1, slow skeletal type	Homo sapiens	151-161	
10616997-1	1999	BACKGROUND: The aim of the present study was to evaluate potential myocardial protection by trimetazidine by measurement of the cardiac marker protein troponin T (TnT) during coronary bypass operations.	Trimetazidine	92-105	troponin T1, slow skeletal type	Homo sapiens	163-166	
10616997-11	1999	In the trimetazidine group, TnT levels were significantly less than those of the placebo group (p < 0.001).	Trimetazidine	7-20	troponin T1, slow skeletal type	Homo sapiens	28-31	
10616997-15	1999	CONCLUSIONS: These results obtained by measurement of cardiac TnT suggested that pretreatment with trimetazidine reduces ischemic-reperfusion damage during coronary bypass operations but did not affect postoperative hemodynamics.	Trimetazidine	99-112	troponin T1, slow skeletal type	Homo sapiens	62-65